TKNO Q4 2024 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9M+17.8% YoY

Gross Profit

$2M23.0% margin

Operating Income

-$6M-60.7% margin

Net Income

-$6M-61.7% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-3.2%

Cash Flow

Operating Cash Flow

-$936,000

Free Cash Flow

-$2M

Stock-Based Comp.

$766,000

Balance Sheet

Total Assets

$119M

Total Liabilities

$36M

Stockholders' Equity

$82M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$8M	+17.8%
Gross Profit	$2M	$1M	+59.4%
Operating Income	-$6M	-$11M	+48.2%
Net Income	-$6M	-$11M	+46.3%

Revenue Segments

Lab Essentials

$7M74%

Clinical Solutions

$2M20%

Other Product

$597,0006%

Geographic Segments

UNITED STATES

$9M95%

Non-US

$501,0005%